BRASTER S.A., the owner of a revolutionary technology for supporting breast cancer diagnostics, plans to introduce a motivation programme for its management staff and key employees. The programme is aimed at increasing the Company’s value by commercialising Braster as soon as possible and increasing the market value of the Company.
Meeting the operational and market criteria laid down by the Company will be the prerequisite for implementing the 2015–2017 motivation programme. One condition will be the sale of at least 10,000 devices on the Polish market starting from next year. In turn, in 2017, the programme requires that at least 50,000 devices be sold domestically and abroad. The programme will also provide for a criterion related to a higher stock price of the Company, calculated as an arithmetical average of closing prices from all sessions in the forth quarter in the given financial year. For 2015, the amount will have to be no less than PLN 17, and in each subsequent year it should be 30% higher than in the previous year and no less than PLN 22.10 and PLN 28.73 in 2016 and 2017, respectively.
"The motivation programme is to have a strong motivation effect on our key employees. The greatest value of BRASTER is its employees who are a decisive factor when it comes to the development prospects ahead of the Company. In my opinion, the Company has a large potential to achieve the goals envisaged in the programme. The programme will provide for an effective tool in the implementation of the Company’s long-term development policy and the fastest possible commercialisation of Braster," says Marcin Halicki, President of the Management Board of BRASTER S.A.
The 2015–2017 motivation programme will be addressed to the key employees and management staff. The programme envisages issuing 240,000 new G-shares. Currently, the capital comprises 5.61 million shares. The issue price of new securities is to reach PLN 13.53, which exceeds the current stock exchange price by 9%. The warrants entitling their holders to take up new shares will be provided to the Board members and individuals indicated by the Supervisory Board. In this regard, a final decision will be made at the next General Meeting.
BRASTER developed a unique technology for producing liquid-crystal matrices, based on which a prototype of the BRASTER device for supporting breast cancer diagnostics was created. The device will be addressed directly to women, and will be placed on the Polish market in the second half of 2016. In 2017, its distribution in Germany and the United Kingdom is to begin. A year later, the device will be placed on the markets of i.a. other European Union countries and the United States.